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March 2012678 Chaerclassification is inadequate for isolated infrarenal aortic
lesions.
The use of covered stents may increase procedural
costs. A proper cost-benefit analysis has not been published
to date. An increased patency rate, as is shown in extensive
iliac disease, combined with a possible decrease in compli-
cations might render the procedure cost effective. Without
randomized studies, however, it might be more cost effec-
tive to reserve covered stenting for cases in which rupture is
suspected. Studies focusing on the use of various tech-
niques in relation to quality adjusted life years are therefore
required.
In conclusion, we have shown that the use of covered
stents for isolated aortic occlusive disease is safe, and related
to low morbidity and excellent patency rates. Comparative
studies with traditional treatment modalities are indicated
to assess the role of covered stents in the treatment strategy
of these lesions.
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The authors report a series of patients with focal infrarenal aortoiliac
occlusive disease that was treated with polytetrafluoroethylene-
covered stenting. Although this is a small series, it provides
valuable information on a problem encountered frequently
enough in clinical practice and shows that primary use of
polytetrafluoroethylene-covered stents is a feasible, effective,
and safe treatment for focal atherosclerotic lesions in the infra-
renal aorta. With a median follow-up of 18 months, there were
no instances of restenosis and no need for any secondary inter-
ventions.
It should be particularly noted that all patients were treated
with a balloon-expandable stent, with no reported adverse
events of aortic rupture. In addition, 67% of the patients had a
patent inferior mesenteric artery, and 33% had aortic mural
thrombus, with no reported cases of bowel ischemia or embo-The reader is correct to be somewhat skeptical of drawing broad
onclusions from a small series that lacks a control group undergoing
ngioplasty or bare-metal stenting, but the results will expand our
nowledge, inform future study, and impact the clinical care of
atients with focal infrarenal aortoiliac occlusive disease. The results of
his series, albeit limited, also seem to dismiss some of the concerns
ssociated with the endovascular treatment of aortic occlusive disease
uch as a high recurrence rate, risk of iatrogenic rupture, risk of colonic
schemia, and the presence of heavily calcified lesions that would be
esistant to angioplasty and stenting.
Stenting for focal infrarenal aortoiliac occlusive disease appears
o be an attractive alternative treatment option for such patients.
owever, longer follow-up, and as the authors rightfully conclude,
dditional comparative studies with traditional treatment modali-
ies, are needed before considering the use of covered stents as the
rst-line standard treatment.
